|Mr. Gil Beyen BVBA||Chairman & CEO||449.66k||N/A||1962|
|Mr. Jérôme Bailly Pharm.D.||VP, Director of Pharmaceutical Operations & Deputy GM||223.14k||N/A||1979|
|Mr. Eric Soyer Ph.D.||CFO & COO||N/A||N/A||1966|
|Dr. Alexander Scheer||Chief Scientific Officer||N/A||N/A||1962|
|Naomi Eichenbaum||Director Investor Relations||N/A||N/A||N/A|
ERYTECH Pharma S.A., a biopharmaceutical company, develops therapies for severe forms of cancer and orphan diseases. It is developing a pipeline of product candidates targeting solid and liquid tumors for patients with high unmet medical needs. The company's lead product candidate is eryaspase, which is used for the treatment of severe solid tumors, including pancreatic cancer and in acute lymphoblastic leukemia. It is preparing for the launch of a pivotal Phase III clinical trial of eryaspase in the United States and Europe. ERYTECH Pharma S.A. has research collaborations with the Fox Chase Cancer Center to advance the preclinical development of erymethionase for the treatment of homocystinuria and with Queen's University of Canada to advance the preclinical development of eryminase for the treatment of arginase-1-deficiency. ERYTECH Pharma S.A. was founded in 2004 and is based in Lyon, France.
ERYTECH Pharma S.A.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.